奥美拉唑联合氟哌噻吨美利曲辛治疗中重度非糜烂性胃食管反流病疗效

The clinical efficacy of omeprazole combined with flupentixol and melitracen in the treatment of Non-erosive reflux disease

目的分析奥美拉唑联合氟哌噻吨美利曲辛对中重度非糜烂性胃食管反流(NERD)患者的临床疗效。方法将126例NERD患者随机分成两组,观察组(63例)接受奥美拉唑联合氟哌噻吨美利曲辛治疗,对照组(63例)只接受奥美拉唑治疗。比较两组患者临床疗效、不良反应情况,以及抑郁与焦虑症状改善情况。结果观察组显效率61.9%,总有效率85.7%,对照组显效率38.1%,总有效率71.4%,两组临床疗效比较差异有统计学意义(P<0.05);观察组不良反应发生率显著性低于对照组(P<0.05)。经过治疗后观察组抑郁、焦虑的状态显著性优于对照组(P<0.05)。结论奥美拉唑联合氟哌噻吨美利曲辛在治疗非糜烂性胃食管反流中具有良好的疗效,复发率低且不良反应小,值得推广应用。

Objective To study the clinical efficacy of omeprazole combined with flupentixol and melitracen for the patients with Non-erosive reflux disease（NERD）. Methods 126 patients with NERD were randomly divided into two groups. Patients in observed group （63 cases） were treated by omeprazole combined with flupentixol and melitracen, while others （63cases） were treated by omeprazole only. Clinical efficacies, the occurrence of ADR, recurrence rate and scores of HAMA and HAMD were compared. Results The cure rate and total effective rate of observed group were 61.9% and 85.7%, while those of control group were 38.1% and 71.4%. There was significant difference between the two groups （P 〈 0.05）. The occurrence of ADR in observation group was significantly lower than that in control group（P 〈 0.05）. The scores of HAMA, HAMD in observation group was significantly lower than control group （P 〈 0.05）. Conclusion The treatment of omeprazole combined with flupentixol and melitracen for NERD has curative clinical efficacy, lower recurrence rate and less adverse reaction, and is worth of clinic application.